-
(Morningside Healthcare Limited) Small number of blisters containing Buprenorphine 8mg Sublingual Tablets packed in cartons labelled Natzon 0.4mg Sublingual Tablets 鈥� class 2 action within 48 hours. (EL (13)A/23)
-
(Eli Lilly Nederland B.V.) Remaining stocks of affected batch should be quarantined and returned to original supplier for credit 鈥� class 2 action within 48 hours. (EL (13)A/22)
-
(Teva UK Limited) Remaining stock should be quarantined and returned to original supplier for credit 鈥� class 3 action within 5 days. (EL (13) A/21)
-
(Patterson Medical) May cause the user to fall. (MDA/2013/060)
-
(Wockhardt UK Limited) Remaining stocks of affected batches should be quarantined and returned to original supplier for credit 鈥� class 2 action within 48 hours (EL (13)A/19)
-
(Pinewood Laboratories Limited) Remaining stocks of the affected batches should be quarantined and returned to the original supplier for credit 鈥� class 2 action within 48 hours. (EL (13)A/18)
-
(Philips) Motorised geometry control system will reboot if users attempt simultaneous powered and manual movement of the C-arm. (MDA/2013/045R)
-
(B Braun Melsungen AG and Fresenius Kabi Limited) Increased risk of renal dysfunction and mortality in critically ill or septic patients鈥� class 1 action within 48 hours. (EL (13)A/18)
-
(Philips) Table will reboot if users attempt a powered and manual movement at the same time. (MDA/2013/045)
-
(Medtronic) 4 field safety notices concerning these products. (MDA/2013/042)
-
(Gilead Sciences International Limited) Remaining stocks of affected batches should be quarantined and returned to the original supplier for credit 鈥� class 1 action now. (EL (13)A/17)
-
(Glaxo Wellcome UK Ltd) Source of possible contamination is believed to be sucrose used within this formulation of Questran 鈥� potential risk of glass fragments in bottles due to defect identified in very small number of bott鈥�
-
(Bristol-Myers Squibb Pharmaceuticals Limited) Source of possible contamination is believed to be sucrose used within this formulation of Questran 鈥� class 2 action within 48 hours. (EL (13)A/15)
-
(Medtronic) May lead to severe hypoglycaemia (low blood glucose) or severe hyperglycaemia (high blood glucose). (MDA/2013/035)
-
(All manufacturers and models) Can lead to potential periods of asystole, syncope and possible death. (MDA/2013/032)
-
(Aurum Pharmaceuticals Limited (trading as Martindale Pharma)) Replaces drug alert issued on 29 April 2013 (EL 13(A)13 Rev 1)
-
(All models and manufacturers) Be aware of the various maximum implant durations for safe retrieval for each IVC filter model. (MDA/2013/028)
-
(Pfizer Limited) Very small number of ampoules containing glass particles identified 鈥� class 3 action within 5 days. (EL (13)A/14)
-
(Aurum Pharmaceuticals Limited (trading as Martindale Pharma)) Pre-filled syringes from affected batches should be used with caution.鈥� class 3 action within 5 days. (EL 13(A)13)
-
(Teva UK Limited) results of assays carried out during routine stability studies did not comply with the required specification 鈥� class 3 action within 5 days. (EL 13(A)11)
-
(Novartis Pharmaceuticals UK) Increased risk of malignancies with long -term use of calcitonin 鈥� class 2 action within 48 hours. (EL 13(A)11)
-
(All manufacturers) Ensure detergent and disinfectant wipes are compatible with the device. (MDA/2013/019)
-
(Hospira) Due to pump faults. (MDA/2013/016)
-
(RAD Neurim Pharmaceuticals EEC Limited) Error in batches distributed since 11 February 2013. (EL (13)A/10)
-
[Archived] (Finsbury Orthopaedics Ltd) Do not implant ADEPT庐 12/14 modular head devices. (MDA/2013/010)
-
(Hospira UK Limited) Visually inspect vials for particulate matter prior to use and do not use if crystals are found - Class 4 medicines defect information (EL (13)A/09)
-
(Mylan) Carton incorrectly states "For children 2 to 5 years" but patient information leaflet (PIL) correctly states "For children 6 to 14 years" 鈥� class 2 action within 48 hours. (EL (13)A/08)
-
(Sanofi-aventis) Remaining stocks of the affected batches should be quarantined and returned to the original supplier for credit 鈥� class 2 action within 48 hours. (EL (13)A/07)
-
(Cambridge Healthcare Supplies Limited on behalf of Typharm Limited) Remaining stocks of the affected batches should be quarantined and returned to Cambridge Healthcare Supplies Limited 鈥� class 2 action within 48 hours. (EL 鈥�
-
(ratiopharm GmbH) Corrected batch numbers from EL (13)A/04 鈥揷lass 3 action within 5 days. (EL (13)A/04 Rev 1)
-
(Hospira) Due to insulation abrasion. (MDA/2013/007)
-
(Hospira) If pump is running on mains power and software detects that battery cannot be fully recharged, an alarm will sound and infusion will stop. (MDA/2013/006)
-
(Auden Mckenzie Ltd) Small number may contain 3 blister strips 鈥揷lass 4 caution in use. (EL (13)A/05)
-
(Merck Sharp & Dohme Ltd) Being recalled as a precaution because results of assays for routine stability studies did not comply with required specification class 3 action within 5 days. (EL (13)A/03)
-
(Merck Sharp & Dohme Ltd) Study showed failure to reduce major vascular events and increase in non-fatal serious adverse events 鈥� class 2 action within 48 hours. (EL (13)A/02)
-
(OPD Laboratories Limited) Recall as some packs have incorrectly-labelled blister strips 鈥� class 2 action within 48 hours. (EL (13)A/01)
-
(Merck Sharp & Dohme Limited trading as Organon Laboratories Limited) Technical portion of leaflet aimed at the healthcare professional omitted. (EL (12)A/35)
-
(Various manufacturers) Check labels and instructions for use to establish if products contain chlorhexidine prior to use on patients with a known allergy. (MDA/2012/075)
-
(Sanofi Pasteur MSD) Some batches may have antigen levels below required specification 鈥� class 2 action within 38 hours. (EL (12)A/33)
-
(Pfizer Limited) Clarification of confusion resulting from amended labels and patient information leaflet 鈥� class 4 caution in use. (EL (12)A/31)
-
(Various manufacturers) Leads to dislodgement of the tube with subsequent risk of airway loss. (MDA/2012/062)
-
(Special Products Ltd) Packs containing the new syringe to be distributed from September 2012 鈥� class 4 caution in use - class 4 caution in use. (EL (12)A/26)
-
GlaxoSmithKline UK are recalling multiple batches of 125ml bottles of the above product. This is due to incorrect dosing instructions on the patient information leaflet advising patients to take half the recommended dose - c鈥�
-
(Actavis UK Ltd) Use of incorrect blister foil which fails to meet the specification for child resistancen 鈥� class 2 action within 48 hours. (EL (12)A/24)
-
(Invacare) Should be appropriately decontaminated between each patient use. (MDA/2012/038)
-
[Archived] (All) MHRA issues updated information and advice for the follow-ups of patients implanted with metal-on-metal (MoM) hip replacements. (MDA/2012/036)
-
(Lincoln Medical Limited) Potential problem could result in a failure to deliver any adrenaline at all in an emergency situation 鈥� class 2 action within 48 hours. (EL (12)A/20)
-
(Teva UK and Numark liveries) Remaining stock should be returned to wholesaler for credit 鈥� class 3 action within 5 days. (EL (12)A/13)
-
(Q-Med AB - a Galderma division) problem with use of Macrolane VRF20 and Macrolane VRF30 for breast augmentation which can make diagnosis of breast cancer more difficult. (MDA/2012/022)
-
(All manufacturers) foam heads of oral swabs may detach from the stick during use, which may present a choking hazard for patients. (MDA/2012/020)